Non Small Cell Lung Carcinoma Clinical Trial
Official title:
A Randomized Phase II Trial of Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer.
The optimal strategy in advanced non small cell lung cancer with stable disease is not well known. There is no published study assessing an early change of chemotherapeutic drugs in these patients.Accordingly, we conduct this trial with the objective to improve the rate of objective responses by the switch to another doublet after 2 cycles of CDDP-gemcitabine association for patients with stable diseases (SD).
Status | Completed |
Enrollment | 227 |
Est. completion date | June 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Histologically or cytologically proved stage IV or pleural stage III NSCLC (neoplastic pleurisy confirmed). - Metastatic relapses allowed in not irradiated area. - Age between 18 and 70 years - Chemonaïve patients - At least one measurable target lesion according to recist criteria in non previously irradiated area. - Performance status < 2 - Normal hepatic and renal function, absolute neutrophil count >1,5 giga/l, platelets >100 giga/l. - Written informed consent. - Life expectancy > 12 weeks. Exclusion Criteria: - SCLC, bronchial-alveolar and neuro-endocrine carcinoma. - Previous chemotherapeutic treatment. - Symptomatic brain metastases. - Superior vena cava syndrome. - Other concomitant diseases: heart failure, angina pectoris, arrhythmia , recent myocardial infarction. - Peripheral neuropathy grade =2. - Past or concomitance of another cancer except baso-cellular carcinoma of the skin or in situ cervical carcinoma. - Hypersensitivity to paclitaxel or polysorbate 80. - Pregnancy or breast feeding. - Any concomitant radiotherapy, except palliative bone irradiation. - Follow-up of the patient impossible. - Prisoners. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Service de Pneumologie | Beauvais | |
France | Service de Pneumologie | Bordeaux | |
France | Service de Pneumologie | Charleville Mezière | |
France | Service de Pneumologie | Créteil | |
France | Service de Pneumologie | Draguignan | |
France | Service de Pneumologie | Elbeuf | |
France | Service de Pneumologie | Gap | |
France | Service de Pathologie Respiratoire | Limoges | |
France | Service de Pneumologie, Hôpital de la Croix Rousse | Lyon | |
France | Service de Pneumologie | Mantes La Jolie | |
France | Département des Maladies Respiratoires | Marseille | |
France | Service de Pneumologie-Allergologie | Martigues | |
France | Service de Pneumologie | Meaux | |
France | Service de Pneumologie | Mulhouse | |
France | Service de Pneumologie - Hôpital St Antoine | Paris | |
France | Service de Pneumologie, Hôpital Pontchailloux | Rennes | |
France | Hôpital Charles Nicolle, Service de Pneumologie | Rouen | |
France | Service de Pneumologie, Hôpital Bois Guillaume | Rouen | |
France | Service de Pneumologie, Hôpital Nord | saint Etienne | |
France | Service de Pathologie Respiratoire | Toulon naval | |
France | Service de Pneumologie | Villefranche |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Limoges | Groupe Français de Pneumologie Cancérologie (GFPC) |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 1-Complete response | |||
Primary | 2-Partial response | |||
Primary | 3-Stable disease | |||
Primary | 4-Progression | |||
Secondary | -Toxicity (NCI-CTC criteria) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01229150 -
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
|
Phase 2 | |
Terminated |
NCT00592007 -
Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01999738 -
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01941316 -
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00111839 -
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
|
Phase 2 | |
Completed |
NCT00181532 -
Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC
|
Phase 2 | |
Completed |
NCT00864266 -
Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer
|
N/A | |
Completed |
NCT00890903 -
Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)
|
N/A | |
Completed |
NCT00635791 -
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT00727350 -
Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma.
|
Phase 2 | |
Completed |
NCT01209520 -
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
|
N/A | |
Active, not recruiting |
NCT00759382 -
Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
|
||
Completed |
NCT00087711 -
A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT00252798 -
ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT02938624 -
Anti PD-1 Neo-adjuvant Treatment for NSCLC
|
Phase 1 | |
Terminated |
NCT00661011 -
Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy
|
Phase 2 | |
Completed |
NCT00608868 -
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
|
Phase 4 | |
Terminated |
NCT00234468 -
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
|
Phase 3 | |
Completed |
NCT00193921 -
Chemoradiotherapy in Patients With Localised Lung Cancer
|
Phase 2 | |
Completed |
NCT00252746 -
ZD6474 Phase IIa Dose Finding Multicentre Study
|
Phase 2 |